Select a medication above to begin.
Voydeya
danicopan
Black Box Warnings .
Appropriate Use
restricted distribution program (VOYDEYA REMS) due to risk of serious infections; prescribers and pharmacies must be certified and enroll at 1-888-765-4747 or www.voydeyarems.com
Serious Infections
may occur, especially those caused by encapsulated bacteria, such as Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae type B; life-threatening and fatal cases have occurred with complement inhibitors; may become rapidly life-threatening or fatal if not recognized and treated early; complete or update vaccination for encapsulated bacteria, specifically Streptococcus pneumoniae and Neisseria meningitidis at least 2wk before tx start, unless tx delay risks outweigh serious infection risk; give antibacterial prophylaxis if urgent tx indicated in patient not up to date with vaccines, and administer vaccines ASAP; comply with ACIP recommendations for vaccinations against encapsulated bacteria in patients receiving a complement inhibitor; revaccinate per ACIP recommendations, considering tx duration; patients at incr. risk for invasive disease caused by encapsulated bacteria even if antibodies developed after vaccination; monitor for early signs of serious infection and evaluate immediately if infection suspected
Adult Dosing .
Dosage forms: TAB: 50 mg, 100 mg
Restricted Distribution in US
- [1-888-765-4747 or www.voydeyarems.com]
paroxysmal nocturnal hemoglobinuria, add-on tx
- [150-200 mg PO TID]
- Start: 150 mg PO TID; Info: for patients with extravascular hemolysis; use with eculizumab or ravulizumab; may incr. dose to 200 mg PO TID if Hgb not incr. by >2 g/dL after 4wk, if transfusion required in previous 4wk, or if clinically warranted to achieve Hgb response
renal dosing
- [see below]
- renal impairment: not defined; Info: caution advised if eGFR <30
- HD/PD: not defined
hepatic dosing
- [see below]
- Child-Pugh Class C: avoid use
Peds Dosing .
Peds dosing is currently unavailable or not applicable for this drug.
Contraindications / Cautions .
- hypersensitivity to drug or ingredient
- encapsulated bacterial infection, active serious
- N. meningitidis infection, active serious
- Streptococcus pneumoniae infection, active serious
- Haemophilus influenzae infection, active serious
- patients unvaccinated against N. meningitidis
- patients unvaccinated against Streptococcus pneumoniae
- hepatic impairment, Child-Pugh Class C
- avoid: breastfeeding during tx and x3 days after D/C
- caution: eGFR <30
- caution: systemic infection, active
- caution: upon D/C
Drug Interactions .
Overview
danicopan
complement inhibitor
- BCRP inhibitor
- P-gp inhibitor, moderate
- immunomodulatory effects
Contraindicated
- BCG live intravesical
- colchicine
- talimogene laherparepvec
Avoid/Use Alternative
- alpelisib
- apixaban
- cladribine oral
- dabigatran
- doxorubicin
- ensartinib
- etrasimod
- lenacapavir
- natalizumab
- neratinib
- pazopanib
- pimecrolimus topical
- pralsetinib
- relugolix
- repotrectinib
- rivaroxaban
- sirolimus albumin-bound
- topotecan
- venetoclax
Monitor/Modify Tx
- afatinib
- atorvastatin
- avatrombopag
- carfilzomib
- carvedilol
- cyclosporine
- digoxin
- edoxaban
- enfortumab vedotin
- everolimus
- fluvastatin
- irinotecan
- lapatinib
- lefamulin
- lovastatin
- mavorixafor
- methotrexate
- mitomycin
- mitoxantrone
- morphine
- pitavastatin
- pravastatin
- quinidine (antiarrhythmic)
- quinidine (CYP2D6 inhibitor)
- ranolazine
- red yeast rice
- rimegepant
- riociguat
- rosuvastatin
- simvastatin
- sipuleucel-T
- sirolimus
- tacrolimus
- talazoparib
- tenofovir alafenamide
- tenofovir disoproxil
- ubrogepant
Caution Advised
- abatacept
- abemaciclib
- abrocitinib
- acalabrutinib
- adalimumab
- afamitresgene autoleucel
- aldesleukin
- alemtuzumab
- aliskiren
- anakinra
- anifrolumab
- anti-thymocyte globulin
- atidarsagene autotemcel
- avacopan
- axicabtagene ciloleucel
- azacitidine
- azathioprine
- baricitinib
- basiliximab
- beclomethasone inhaled
- beclomethasone nasal
- belatacept
- belimumab
- belinostat
- bendamustine
- betamethasone
- bimekizumab
- blinatumomab
- bortezomib
- brentuximab vedotin
- brexucabtagene autoleucel
- brodalumab
- budesonide
- budesonide inhaled
- budesonide nasal
- budesonide rectal
- busulfan
- cabazitaxel
- canakinumab
- carboplatin
- carmustine
- certolizumab pegol
- chlorambucil
- ciltacabtagene autoleucel
- cisplatin
- cladribine injection
- clobetasol ophthalmic
- clofarabine
- coccidioides immitis skin test antigen
- copanlisib
- corticotropin
- cortisone
- crovalimab
- cyclophosphamide
- cytarabine
- dactinomycin
- daratumumab
- darolutamide
- daunorubicin
- decitabine
- deflazacort
- delgocitinib topical
- deucravacitinib
- deuruxolitinib
- dexamethasone
- dexamethasone ophthalmic
- difluprednate ophthalmic
- dimethyl fumarate
- dinutuximab
- diroximel fumarate
- docetaxel
- dupilumab
- duvelisib
- eculizumab
- efgartigimod alfa
- elivaldogene autotemcel
- elotuzumab
- elranatamab
- emapalumab
- epcoritamab
- epirubicin
- eribulin
- etanercept
- etoposide
- etuvetidigene autotemcel
- fingolimod
- floxuridine
- fludarabine
- fludrocortisone
- flunisolide nasal
- fluocinolone intravitreal
- fluorometholone ophthalmic
- fluticasone furoate
- fluticasone propionate
- fruquintinib
- gemtuzumab ozogamicin
- glecaprevir
- glofitamab
- golimumab
- guselkumab
- hydrocortisone
- hydrocortisone ophthalmic
- hydroxyurea
- ibritumomab tiuxetan
- ibrutinib
- icotrokinra
- idarubicin
- idecabtagene vicleucel
- idelalisib
- ifosfamide
- inebilizumab
- infliximab
- inotuzumab ozogamicin
- iptacopan
- isatuximab
- ixabepilone
- ixekizumab
- lebrikizumab
- leflunomide
- lenalidomide
- lifileucel
- linvoseltamab
- lisocabtagene maraleucel
- lomustine
- loncastuximab tesirine
- loteprednol ophthalmic
- lymphocyte immune globulin, anti-thymocyte globulin
- maraviroc
- melphalan
- mercaptopurine
- methylprednisolone
- mirikizumab
- mogamulizumab
- momelotinib
- mometasone implant
- mometasone inhaled
- mometasone nasal
- monomethyl fumarate
- mosunetuzumab
- mycophenolate mofetil
- mycophenolic acid
- nadofaragene firadenovec intravesical
- naldemedine
- narsoplimab
- nelarabine
- nipocalimab
- obecabtagene autoleucel
- obinutuzumab
- ocrelizumab
- ofatumumab
- oxaliplatin
- ozanimod
- paclitaxel
- pegcetacoplan
- pentostatin
- pibrentasvir
- pirtobrutinib
- polatuzumab vedotin
- pomalidomide
- ponatinib
- ponesimod
- pozelimab
- prednisolone
- prednisolone ophthalmic
- prednisone
- procarbazine
- quizartinib
- ravulizumab
- regorafenib
- rilonacept
- rilzabrutinib
- risankizumab
- ritlecitinib
- rituximab
- romidepsin
- ropeginterferon alfa-2b
- rozanolixizumab
- ruxolitinib
- ruxolitinib topical
- sarilumab
- satralizumab
- secukinumab
- seladelpar
- selinexor
- sibeprenlimab
- silodosin
- siltuximab
- siponimod
- spesolimab
- sulfasalazine
- sutimlimab
- tafasitamab
- talquetamab
- tarlatamab
- teclistamab
- temozolomide
- temsirolimus
- teplizumab
- teriflunomide
- thioguanine
- thiotepa
- tildrakizumab
- tisagenlecleucel
- tocilizumab
- tofacitinib
- trabectedin
- tralokinumab
- triamcinolone
- tuberculin purified protein derivative
- ublituximab
- upadacitinib
- ustekinumab
- vamorolone
- vedolizumab
- vilobelimab
- vinblastine
- vincristine
- vinorelbine
- voclosporin
- zanubrutinib
- zilucoplan
Adverse Reactions .
Serious Reactions
- meningococcal infection
- Streptococcus pneumoniae infection
- Haemophilus influenzae infection
- infection, serious
- hyperlipidemia
- pancreatitis
- cholecystitis
- hemolysis upon D/C
Common Reactions
- hypercholesterolemia
- headache
- vomiting
- fever
- ALT incr.
- pancreatitis
- cholecystitis
- bilirubin incr.
- HTN
- extremity pain
- triglycerides incr.
Safety/Monitoring .
Monitoring Parameters
LFTs at baseline, then periodically; lipid panel; signs/symptoms of serious infection during tx and x1wk after D/C; Hgb, LDH, signs/symptoms of hemolysis for at least 2wk after D/C
Pregnancy/Lactation .
Pregnancy
Clinical Summary
benefits outweigh risks during pregnancy; no human data available; no known risk of embryo-fetal toxicity based on animal data at 18x and 25x MRHD
Lactation
Clinical Summary
avoid breastfeeding during tx and x3 days after D/C; no human data available to assess risk of infant harm or effects on milk production
Pharmacology .
Metabolism: for danicopan: oxidation, reduction, hydrolysis; CYP450: minimal
Excretion: for danicopan: feces 69% (3.6% unchanged), urine 25% (0.5% unchanged); Half-life: 7.9h
Subclass: Complement Inhibitors, Hematologic
Mechanism of Action
for danicopan: binds alternative complement pathway factor D reversibly, regulating complement factor B cleavage and its downstream complement activation cascade, preventing C3 fragment-mediated extravascular hemolysis
Formulary .
No Formulary Selected
Join Now to View Patient Handouts!
Create a FREE epocrates Online account to access patient medication instructions. Your patients and caregivers will appreciate you printing these friendly handouts, available in English and Spanish. Each handout addresses common concerns such as how to take the medication, and possible side effects.
Current Members: Sign In.
Pill Pictures
Join Now to View Pill Pictures!
Create a FREE epocrates Online account to access full-color images of medications within the drug monograph.
Current Members: Sign In.